Published in Genes Dev on October 01, 1994
A compilation of composite regulatory elements affecting gene transcription in vertebrates. Nucleic Acids Res (1995) 4.93
Molecular genetics of the RNA polymerase II general transcriptional machinery. Microbiol Mol Biol Rev (1998) 4.49
Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro. Genes Dev (1998) 2.27
A class of activation domains interacts directly with TFIIA and stimulates TFIIA-TFIID-promoter complex assembly. Mol Cell Biol (1995) 1.85
A mechanism for repression of class II gene transcription through specific binding of NC2 to TBP-promoter complexes via heterodimeric histone fold domains. EMBO J (1996) 1.81
Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID. EMBO J (1995) 1.76
Uncleaved TFIIA is a substrate for taspase 1 and active in transcription. Mol Cell Biol (2006) 1.51
The coactivator p15 (PC4) initiates transcriptional activation during TFIIA-TFIID-promoter complex formation. EMBO J (1995) 1.46
TFIID and human mediator coactivator complexes assemble cooperatively on promoter DNA. Genes Dev (2002) 1.45
Human TATA-binding protein-related factor-2 (hTRF2) stably associates with hTFIIA in HeLa cells. Proc Natl Acad Sci U S A (1999) 1.44
Dissection of TALE-dependent gene activation reveals that they induce transcription cooperatively and in both orientations. PLoS One (2017) 1.37
Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo. Mol Cell Biol (1996) 1.31
Positive and negative functions of the SAGA complex mediated through interaction of Spt8 with TBP and the N-terminal domain of TFIIA. Genes Dev (2004) 1.29
A human TATA binding protein-related protein with altered DNA binding specificity inhibits transcription from multiple promoters and activators. Mol Cell Biol (1999) 1.27
Mutations on the DNA-binding surface of TATA-binding protein can specifically impair the response to acidic activators in vivo. Mol Cell Biol (1995) 1.25
Identification of poly(ADP-ribose) polymerase as a transcriptional coactivator of the human T-cell leukemia virus type 1 Tax protein. J Virol (2000) 1.23
The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Mol Cell Biol (1999) 1.22
Mechanism of synergy between TATA and initiator: synergistic binding of TFIID following a putative TFIIA-induced isomerization. Genes Dev (1997) 1.21
DA-complex assembly activity required for VP16C transcriptional activation. Mol Cell Biol (1998) 1.20
The general transcription factors IIA, IIB, IIF, and IIE are required for RNA polymerase II transcription from the human U1 small nuclear RNA promoter. Mol Cell Biol (1999) 1.18
Characterization of the basal inhibitor of class II transcription NC2 from Saccharomyces cerevisiae. Nucleic Acids Res (1996) 1.18
A new class of activation-defective TATA-binding protein mutants: evidence for two steps of transcriptional activation in vivo. Mol Cell Biol (1996) 1.18
TAFII-independent activation mediated by human TBP in the presence of the positive cofactor PC4. EMBO J (1998) 1.17
Human general transcription factor TFIIA: characterization of a cDNA encoding the small subunit and requirement for basal and activated transcription. Proc Natl Acad Sci U S A (1995) 1.16
Corepressor required for adenovirus E1B 55,000-molecular-weight protein repression of basal transcription. Mol Cell Biol (1999) 1.12
Requirement for transcription factor IIA (TFIIA)-TFIID recruitment by an activator depends on promoter structure and template competition. Mol Cell Biol (1997) 1.10
The transcriptional corepressor DSP1 inhibits activated transcription by disrupting TFIIA-TBP complex formation. EMBO J (1996) 1.07
Association of transcription factor IIA with TATA binding protein is required for transcriptional activation of a subset of promoters and cell cycle progression in Saccharomyces cerevisiae. Mol Cell Biol (1998) 1.07
Potential targets for HSF1 within the preinitiation complex. Cell Stress Chaperones (2000) 1.05
Interaction of the human T-cell lymphotropic virus type 1 tax transactivator with transcription factor IIA. Mol Cell Biol (1996) 1.03
Identifying a species-specific region of yeast TF11B in vivo. Mol Cell Biol (1996) 1.01
Acetyl coenzyme A stimulates RNA polymerase II transcription and promoter binding by transcription factor IID in the absence of histones. Mol Cell Biol (2000) 1.01
Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Dev Cell (2013) 1.01
Differential cellular requirements for activation of herpes simplex virus type 1 early (tk) and late (gC) promoters by ICP4. J Virol (2004) 0.99
Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation. J Virol (2001) 0.98
Transactivation of the human T-cell lymphotropic virus type 1 Tax1-responsive 21-base-pair repeats requires Holo-TFIID and TFIIA. J Virol (1995) 0.97
Transcriptional activation by TFIIB mutants that are severely impaired in interaction with promoter DNA and acidic activation domains. Mol Cell Biol (1997) 0.96
Functional dissection of a human Dr1-DRAP1 repressor complex. Mol Cell Biol (1997) 0.96
Structural and functional interactions of transcription factor (TF) IIA with TFIIE and TFIIF in transcription initiation by RNA polymerase II. J Biol Chem (2001) 0.95
TFIIA interacts with TFIID via association with TATA-binding protein and TAF40. Mol Cell Biol (2001) 0.95
Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex. J Virol (1996) 0.95
Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res (1995) 0.94
Fos-Jun dimerization promotes interaction of the basic region with TFIIE-34 and TFIIF. Mol Cell Biol (1996) 0.93
Interactions of a DNA-bound transcriptional activator with the TBP-TFIIA-TFIIB-promoter quaternary complex. J Biol Chem (2003) 0.93
Expression and purification of recombinant human c-Fos/c-Jun that is highly active in DNA binding and transcriptional activation in vitro. Nucleic Acids Res (2001) 0.93
Analysis of TFIIA function In vivo: evidence for a role in TATA-binding protein recruitment and gene-specific activation. Mol Cell Biol (1999) 0.93
Separation of the transcriptional coactivator and antirepression functions of transcription factor IIA. Proc Natl Acad Sci U S A (1996) 0.93
TFIIB recognition elements control the TFIIA-NC2 axis in transcriptional regulation. Mol Cell Biol (2008) 0.90
Cleavage and proteasome-mediated degradation of the basal transcription factor TFIIA. EMBO J (2004) 0.90
Transcriptional activation in yeast cells lacking transcription factor IIA. Genetics (1999) 0.90
The major histocompatibility complex class II Ea promoter requires TFIID binding to an initiator sequence. Mol Cell Biol (1996) 0.88
Single-molecule fluorescence resonance energy transfer shows uniformity in TATA binding protein-induced DNA bending and heterogeneity in bending kinetics. Biochemistry (2012) 0.87
Phosphorylation of TFIIA stimulates TATA binding protein-TATA interaction and contributes to maximal transcription and viability in yeast. Mol Cell Biol (1999) 0.87
A TATA-binding protein mutant defective for TFIID complex formation in vivo. Mol Cell Biol (1999) 0.87
Evidence that TAF-TATA box-binding protein interactions are required for activated transcription in mammalian cells. Mol Cell Biol (2002) 0.85
p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Mol Cell Biol (2001) 0.82
Nonradioactive, ultrasensitive site-specific protein-protein photocrosslinking: interactions of alpha-helix 2 of TATA-binding protein with general transcription factor TFIIA and transcriptional repressor NC2. Nucleic Acids Res (2008) 0.78
TBP-like protein (TLP) interferes with Taspase1-mediated processing of TFIIA and represses TATA box gene expression. Nucleic Acids Res (2015) 0.76
Taspase1 processing alters TFIIA cofactor properties in the regulation of TFIID. Transcription (2015) 0.76
A Transcription Factor IIA Binding Site Differentially Regulates RNA Polymerase II-Mediated Transcription in a Promoter Context-dependent Manner. J Biol Chem (2017) 0.75
Molecular characterization of ScTFIIAgamma, encoding the putative TFIIA small subunit from sugarcane. Plant Cell Rep (2010) 0.75
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76
Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science (1984) 9.14
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell (1996) 6.87
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell (1990) 5.73
I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev (1992) 5.67
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 5.52
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev (1990) 4.96
Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis (1986) 4.89
Holo-TFIID supports transcriptional stimulation by diverse activators and from a TATA-less promoter. Genes Dev (1992) 4.85
Enumeration of the oxygen sensitive bacteria usually present in the intestine of healthy mice. Nature (1968) 4.70
Cloning of the beta subunit of the leukocyte adhesion proteins: homology to an extracellular matrix receptor defines a novel supergene family. Cell (1987) 4.70
Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life. BMJ (1992) 4.53
Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol (1986) 4.48
A group of interacting yeast DNA replication genes. Genes Dev (1991) 4.45
Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. Br J Psychiatry (2000) 4.44
Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol (1992) 4.36
Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med (2000) 4.36
Cloning of a transcriptionally active human TATA binding factor. Science (1990) 4.18
Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med (1998) 4.07
Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science (1988) 4.01
Development of the Drosophila mushroom bodies: sequential generation of three distinct types of neurons from a neuroblast. Development (1999) 3.96
High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun (2006) 3.86
Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein. J Virol (1986) 3.82
Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ (2001) 3.81
Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature (1987) 3.77
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A (1991) 3.76
Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. Am J Gastroenterol (1987) 3.65
Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci U S A (1995) 3.62
Structural conservation in prokaryotic and eukaryotic potassium channels. Science (1998) 3.61
Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57
Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and related bacteria. Int J Syst Bacteriol (1991) 3.46
Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest (2001) 3.41
Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood (2001) 3.39
Laryngotracheal stenosis: a serious complication of percutaneous tracheostomy. Anaesthesia (1994) 3.36
Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem (1998) 3.31
NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol (1993) 3.27
Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem (2001) 3.26
Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet (1986) 3.24
Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell (1998) 3.22
Secondary structure is the major determinant for interaction of HIV rev protein with RNA. Science (1990) 3.11
Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. J Biol Chem (1998) 3.07
The microbial ecology of the large bowel of breast-fed and formula-fed infants during the first year of life. J Med Microbiol (1982) 3.04
Mucus colonization as a determinant of pathogenicity in intestinal infection by Campylobacter jejuni: a mouse cecal model. Infect Immun (1986) 3.03
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest (1993) 2.97
A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. Science (1990) 2.91
Addition of physicians to paramedic helicopter services decreases blunt trauma mortality. Aust N Z J Surg (1999) 2.89
Arabidopsis COP8, COP10, and COP11 genes are involved in repression of photomorphogenic development in darkness. Plant Cell (1994) 2.89
Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev (1990) 2.87
HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Dev (1992) 2.85
The chromosome end in yeast: its mosaic nature and influence on recombinational dynamics. Genetics (1994) 2.70
A body image scale for use with cancer patients. Eur J Cancer (2001) 2.68
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative. Mol Cell Biol (1992) 2.67
Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A (1987) 2.66
Life-threatening reactions after pedodontic sedation: an assessment of narcotic, local anesthetic, and antiemetic drug interaction. J Am Dent Assoc (1983) 2.64
Subcellular localization of the human immunodeficiency virus trans-acting art gene product. J Virol (1988) 2.64
Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology (1990) 2.64
A rapid method for the construction of synthetic genes using the polymerase chain reaction. Biotechniques (1990) 2.64
Identification of sequences important in the nucleolar localization of human immunodeficiency virus Rev: relevance of nucleolar localization to function. J Virol (1990) 2.63
IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol (1996) 2.62
Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition. J Infect Dis (1992) 2.60
Prospective evaluation of patients refused admission to an intensive care unit: triage, futility and outcome. Intensive Care Med (2001) 2.59
An uncultured gastric spiral organism is a newly identified Helicobacter in humans. J Infect Dis (1993) 2.53
Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis. Proc Natl Acad Sci U S A (1989) 2.51
Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes. J Virol (1986) 2.50
Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg (1989) 2.49
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc Natl Acad Sci U S A (1990) 2.47
The mouse intestinal microflora with emphasis on the strict anaerobes. J Exp Med (1971) 2.46
Transcriptional activation of Salmonella typhimurium invasion genes by a member of the phosphorylated response-regulator superfamily. Mol Microbiol (1996) 2.46
A whole blood immunoassay using gold nanoshells. Anal Chem (2003) 2.45
Diagnosis of major chromosome aneuploidies in human preimplantation embryos. Hum Reprod (1993) 2.45
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity. Genes Dev (1992) 2.36
Health status in VA patients: results from the Veterans Health Study. Am J Med Qual (1999) 2.35
Essential roles of Drosophila RhoA in the regulation of neuroblast proliferation and dendritic but not axonal morphogenesis. Neuron (2000) 2.31
GSP1 and GSP2, genetic suppressors of the prp20-1 mutant in Saccharomyces cerevisiae: GTP-binding proteins involved in the maintenance of nuclear organization. Mol Cell Biol (1993) 2.30
Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5. Mol Cell Biol (1996) 2.30
Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences. J Virol (1985) 2.29
Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression. J Virol (1991) 2.26
The urease enzymes of Campylobacter pylori and a related bacterium. J Med Microbiol (1988) 2.25
Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci U S A (1985) 2.25
Helicobacter pylori infection in children: potential clues to pathogenesis. J Pediatr Gastroenterol Nutr (1993) 2.25
Randomised controlled trial of computer assisted management of hypertension in primary care. Br Med J (Clin Res Ed) (1986) 2.24
Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J Immunol (1994) 2.22
Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science (1993) 2.20
Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost (2014) 2.18
Differentiation of subtypes within Leptospira interrogans serovars Hardjo, Balcanica and Tarassovi, by bacterial restriction-endonuclease DNA analysis (BRENDA). J Med Microbiol (1982) 2.17
A new type of transforming growth factor-beta, TGF-beta 3. EMBO J (1988) 2.12
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 2.11
Atypical presentations of pityriasis rosea: case presentations. J Eur Acad Dermatol Venereol (2005) 2.11